Table 1 Clinical and biologic... | American Society of Hematology

Table 1

Clinical and biologic characteristics of the CLL patients used in 2D-DIGE experiments

Patient no.	Age, y	Sex	Binet stage	Rai stage	Matutes†	IGVH	ZAP70	Cytogenetics	CD38	Lymphocyte doubling time, years	BCR response
UM1	89	Male	A	0	5	100%/V1-69/subset 9*	Positive	del11q	Positive	> 1	Yes (25%)
UM2	68	Male	A	0	5	100%/V3-21	Positive	t(6;11;14)	Positive	> 1	Yes (60.4%)
UM3	67	Female	A	III	5	100%/V1-69	Positive	del13q/del17p	Positive	< 1	Yes (42.6%)
M1	64	Male	A	0	5	94.7%/V4-59	Negative	Normal	Negative	> 1	No (12.6%)
M2	76	Male	A	0	4	97.4%/V5-51	Negative	NA	Negative	> 1	No (2%)
M3	65	Male	A	0	5	90.2%/V4-34	Negative	del13q	Negative	> 1	Yes (46.2%)

Patient no.	Age, y	Sex	Binet stage	Rai stage	Matutes†	IGVH	ZAP70	Cytogenetics	CD38	Lymphocyte doubling time, years	BCR response
UM1	89	Male	A	0	5	100%/V1-69/subset 9*	Positive	del11q	Positive	> 1	Yes (25%)
UM2	68	Male	A	0	5	100%/V3-21	Positive	t(6;11;14)	Positive	> 1	Yes (60.4%)
UM3	67	Female	A	III	5	100%/V1-69	Positive	del13q/del17p	Positive	< 1	Yes (42.6%)
M1	64	Male	A	0	5	94.7%/V4-59	Negative	Normal	Negative	> 1	No (12.6%)
M2	76	Male	A	0	4	97.4%/V5-51	Negative	NA	Negative	> 1	No (2%)
M3	65	Male	A	0	5	90.2%/V4-34	Negative	del13q	Negative	> 1	Yes (46.2%)

NA indicates not available.

Analysis of stereotyped BCR and subset definition according to Murray et al.¹⁸

Immunophenotyping scoring system for CLL diagnosis (Matutes scores of 4 or 5 for typical CLL according to Matutes et al³⁴).